Glecaprevir is an NS3 protease inhibitor that prevents the cleavage of the HCV polyprotein and inhibits viral replication. Pibrentasvir is a next-generation NS5A inhibitor that inhibits both viral replication and assembly of virions. Bothdrugshave pangenotypic activity against all genotypes of HCV. The article reviews the results of the clinical trials that studied the efficacy and safety of glecaprevir/pibrentasvir in patients with HCV genotypes 1, 2 and 3 infection (the most common genotypes of HCV in Russia). However, the efficacy of fixed combination was also established in patients with HCV genotype 4, 5 and 6 infection. Glecaprevir/pibrentasvir was effective in difficult to treat patients, i.e. with HIV-conifection, chronic kidney disease and after liver or kidney transplantation.
Chronic hepatitis C, glecaprevir, pibrentasvir, treatment.